The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...
In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...
NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
Medpage Today on MSN22hOpinion
How a Book Is Undermining Progress Against Alzheimer'sSystematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...
The Therapeutic Goods Administration (TGA) of Australia has declined the approval of Leqembi (lecanemab) as a treatment for ...
Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
A special edition of the journal Science focuses on women's health, including links between estrogen and dementia, at a time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback